Skip to content

CJC-1295 Without DAC

Emerging evidence

CJC-1295 (no DAC) is a GHRH analog with a short half-life, allowing pulsatile dosing. Paired with Ipamorelin it can extend the GH release window without sustained elevation. Not medical advice; consult a provider.

How CJC-1295 Without DAC works

CJC-1295 no DAC stimulates GHRH receptors with a short half-life. Paired with Ipamorelin it extends the release window while allowing pulsatile dosing vs. sustained elevation.

Researched benefits

  • •Pulsatile dosing; may better mimic natural GH patterns
  • •Often combined with Ipamorelin for synergistic release
  • •No drug-affinity complex (DAC), so shorter duration
  • •Research in body composition and recovery

What it is studied for

  • •GH optimization when pulsatile approach preferred
  • •Recovery and muscle/body composition in research
  • •Stacks with Ipamorelin for extended pulse

Reported side effects and cautions

  • •Injection-site reactions
  • •GH-related effects; IGF-1 and glucose monitoring recommended
  • •Not for active cancer or certain conditions

Dosing protocol described in the literature

Dosage
250-500mcg
Frequency
With Ipamorelin
Administration
Subcutaneous
Cycle
8-16 weeks

GH optimization

Work out the reconstitution for this dose →

Evidence rating: Emerging evidence

Some human data exists but the evidence base is limited — often small studies, narrow indications, or trials still under way.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)Tirzepatide (GLP-1/GIP dual agonist)CagrilintideRetatrutide + Cagrilintide (combination)

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use CJC-1295 Without DAC. Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.